大理药业(603963) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥20,237,388.70, an increase of 47.69% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was -¥7,580,702.04, with a year-to-date net profit of -¥19,735,072.06, reflecting a significant loss[2]. - Total operating revenue for the first three quarters of 2024 was CNY 47,647,377.83, a decrease of 35% compared to CNY 73,273,235.69 in the same period of 2023[16]. - The company reported a net loss of CNY 8,778,200.23 for the first three quarters of 2024, compared to a profit of CNY 10,956,871.83 in the same period of 2023[15]. - The net loss for Q3 2024 was ¥19,735,072.06, compared to a net loss of ¥15,388,969.20 in Q3 2023, reflecting an increase in losses of approximately 28.5%[18]. - The total comprehensive loss for Q3 2024 was ¥19,735,072.06, compared to a comprehensive loss of ¥15,388,969.20 in Q3 2023, marking an increase in losses of about 28.5%[18]. Assets and Liabilities - Total assets at the end of the reporting period were ¥450,203,562.66, a decrease of 4.99% from the previous year[3]. - Total assets decreased to CNY 450,203,562.66 from CNY 473,833,811.62, reflecting a decline in overall asset value[14]. - Current liabilities totaled CNY 77,334,644.14, slightly up from CNY 76,967,820.10 at the end of 2023[15]. - Non-current liabilities decreased to CNY 11,479,005.62 from CNY 15,741,006.56, indicating improved long-term financial stability[15]. Cash Flow - Cash flow from operating activities for the year-to-date was -¥7,929,115.21, indicating a reduction in cash inflow[6]. - Cash flow from operating activities for the first three quarters of 2024 was -¥7,929,115.21, an improvement from -¥33,103,551.66 in the same period of 2023[19]. - Cash inflow from operating activities totaled ¥60,099,886.59 in the first three quarters of 2024, down from ¥90,643,453.16 in the same period of 2023, a decrease of approximately 33.5%[19]. - The ending balance of cash and cash equivalents reached $207.69 million, significantly higher than $16.57 million at the end of the previous period, indicating strong cash reserves[20]. Shareholder Information - The company recorded a total of 15,124 common shareholders at the end of the reporting period[9]. - The top shareholder, Yang Junxiang, holds 51,204,200 shares, representing 23.31% of the total shares[9]. Investment Activities - The company recorded cash inflow from investment activities of ¥325,000,000.00 in the first three quarters of 2024, compared to ¥307,000,000.00 in the same period of 2023, reflecting an increase of approximately 5.9%[19]. - Cash payments for investment activities were $120 million, significantly lower than $285 million in the previous period, indicating a strategic reduction in investment outflows[20]. - Cash payments for the acquisition of fixed assets and intangible assets were $2.04 million, down from $5.48 million, reflecting a decrease in capital expenditures[20]. Risk and Management - The company is under risk of being delisted due to negative net profit and revenue below CNY 100 million, as per the Shanghai Stock Exchange regulations[12]. - The company emphasizes the importance of rational investment and awareness of investment risks to its shareholders[12].